

NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL

Entity Resources and Planned Performance

NHMRC

NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL

Section 1: Entity Overview and Resources	388
1.1 Strategic Direction Statement	388
1.2 Entity Resource Statement	389
1.3 Budget Measures	390
Section 2: Outcomes and Planned Performance	391
2.1 Budgeted Expenses and Performance for Outcome 1	391
Section 3: Budgeted Financial Statements	395
3.1 Budgeted Financial Statements	395
3.2 Budgeted Financial Statements Tables	396

Section 1: Entity Overview and Resources

1.1 STRATEGIC DIRECTION STATEMENT¹

The National Health and Medical Research Council (NHMRC) is the Australian Government's key entity for managing investment in, and the integrity of, health and medical research. NHMRC is also responsible for developing evidence-based health advice for the Australian community, health professionals and governments, and for promoting the highest standards in health and medical research.

In 2018-19, NHMRC will roll out a new grant program, which is the culmination of extensive consultations with the health and medical research community. It will encourage greater creativity and innovation in research, and provide opportunities for talented researchers at all career stages. In 2018-19, NHMRC will implement new ICT solutions that will complement its new grant program by streamlining grant opportunities and assessment processes, to further reduce red tape for the research community.

NHMRC's work will also facilitate and promote the translation of evidence derived from health and medical research into practices and systems designed to prevent illness and improve public health. NHMRC's guidelines and advice support the States and Territories in achieving consistent standards in public and environmental health and in the detection and prevention of illness. NHMRC will also continue to ensure strategic alignment with the Medical Research Future Fund, including opportunities for future collaborations.

The role and functions of NHMRC are set out in the *National Health and Medical Research Council Act 1992*. NHMRC also has statutory obligations under the *Prohibition of Human Cloning for Reproduction Act 2002* and the *Research Involving Human Embryos Act 2002*. NHMRC is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of NHMRC, refer to the current Corporate Plan, available at: www.nhmrc.gov.au/guidelines-publications/nh173

1.2 ENTITY RESOURCE STATEMENT

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (Government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (i.e. appropriations/cash available) basis, whilst the 'Budgeted expenses by outcome' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: NHMRC Resource Statement – Budget Estimates for 2018-19 as at Budget May 2018

	2017-18 Estimated actual \$'000	2018-19 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	11,990	7,831
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	39,005	37,591
s74 retained revenue receipts ^(b)	5,386	6,846
Departmental capital budget ^(c)	171	171
Other services ^(d)		
Equity injection	3,879	250
Total departmental annual appropriations	48,441	44,858
Total departmental resourcing for NHMRC	60,431	52,689



Table 1.1: NHMRC Resource Statement – Budget Estimates for 2018-19 as at Budget May 2018 (continued)

	2017-18 Estimated actual \$'000	2018-19 Estimate \$'000
ADMINISTERED		
Prior year appropriation available	198,460	185,770
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	883,632	882,753
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	883,632	882,753
Special Accounts ^(e)		
Appropriation receipts	817,990	829,324
Appropriation receipts - other entities ^(f)	-	-
Non-appropriation receipts	11,000	11,000
Total Special Accounts	828,990	840,324
Total administered resourcing	1,911,082	1,908,847
Less appropriations drawn from annual or special appropriations above and credited to Special Accounts ^(g)	(817,990)	(829,324)
Total administered resourcing	1,093,092	1,079,523
Total resourcing for NHMRC	1,153,523	1,132,212
	2017-18	2018-19
Average staffing level (number)	177	180

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2018-19 and Appropriation Bill/Act (No. 1, 3, 5) 2017-18.

^(b) Estimated retained revenue receipts under section 74 of the PGPA Act 2013.

^(c) Departmental capital budgets (DCB) are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Refer to Table 3.5 for further details.

For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2018-19 and Appropriation Bill/Act (No. 2, 4, 6) 2017-18.

^(e) For further information on special appropriations and special accounts, refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1 for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

^(f) Appropriation receipts from the Department of Health.

^(g) Appropriation receipts included above.

1.3 BUDGET MEASURES

This section is not applicable to the NHMRC.

Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which Government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to Government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the enhanced Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance criteria described in Portfolio Budget Statements will be read with broader information provided in an entity's Corporate Plans and Annual Performance Statements – included in Annual Reports – to provide an entity's complete performance story.

NHMRC's most recent Corporate Plan is available at:
www.nhmrc.gov.au/guidelines-publications/nh173

NHMRC's most recent Annual Performance Statement is available at:
www.nhmrc.gov.au/guidelines-publications/nh1754



2.1 BUDGETED EXPENSES AND PERFORMANCE

Outcome 1

Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health

Program Contributing to Outcome 1

Program 1.1: Health and Medical Research

Linked Programs

Other Commonwealth entities that contribute to Outcome 1
<p>Department of Health</p> <p>Program 1.1: Health Policy Research and Analysis</p> <p>The Department of Health has policy responsibility for health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future, and drive further medical innovation.</p>

Budgeted Expenses for NHMRC

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses for NHMRC

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Year 1 \$'000	2020-21 Forward Year 2 \$'000	2021-22 Forward Year 3 \$'000
Program 1.1: Health and Medical Research					
Administered expenses					
Ordinary annual services ^(a) to Medical Research Endowment Account	883,632	882,753	854,712	867,532	880,545
Special Accounts Medical Research Endowment Account	(817,990)	(829,324)	(842,766)	(855,407)	(868,238)
	853,091	844,199	844,732	863,136	878,490
Departmental expenses					
Departmental appropriation ^(b)	44,391	44,437	42,646	41,827	41,192
Expenses not requiring appropriation in the Budget year ^(c)	3,418	2,708	2,708	2,708	2,708
Operating deficit (surplus)	-	-	-	-	-
Total for Program 1.1	966,542	944,773	902,032	919,796	934,697
Total expenses for Outcome 1	966,542	944,773	902,032	919,796	934,697

	2017-18	2018-19
Average staffing level (number)	177	180

^(a) Appropriation (Bill No. 1) 2018-19 and Appropriation Bill/Act (No. 1, 3, 5) 2017-18.

^(b) Departmental appropriation combines 'Ordinary annual services (Appropriation Bill No. 1)' and 'Revenue from independent sources (s74)'.
^(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

Movement of Funds

There were no movements of Administered funds between years.

Planned Performance for NHMRC

Table 2.1.2 below details the performance criteria for the program associated with Outcome 1. It also summarises how the program is delivered and where 2018-19 Budget measures have materially changed the program.

Table 2.1.2: Performance Criteria for NHMRC

Purpose
To fund high quality health and medical research and build research capability, support the translation of health and medical research into better health outcomes and promote the highest standards of ethics and integrity in health and medical research.
Outcome 1
Improved health and medical knowledge, including through funding research, translating research findings into evidence-based clinical practice, administering legislation governing research, issuing guidelines and advice for ethics in health and the promotion of public health.
Program 1.1: Health and Medical Research
The Australian Government, through NHMRC, will continue to invest in innovative health and medical research that is undertaken within a framework focused on promoting quality, integrity and ethics. The knowledge created will contribute to addressing national health priorities with the aim of improving health care and the health status of all Australians. In 2018-19, NHMRC will begin the rollout of its new grant program to fund high quality research to achieve the best quality health outcomes, while reducing the burden on applicants and reviewers.
Delivery
<p>A. Investment</p> <ul style="list-style-type: none"> • Support research across the four pillars of health research: biomedical, clinical, public health and health services research. • Fund the highest quality research and researchers. • Continue funding of research and capacity building to support better health outcomes for Aboriginal and Torres Strait Islander peoples. • Continue to boost Australia's dementia research capacity and fund priority research and translation into prevention, better diagnosis, treatment and care for people with dementia. <p>B. Translation</p> <ul style="list-style-type: none"> • Support leadership in research and evidence-based health care through the designation and promotion of Advanced Health Research and Translation Centres and Centres for Innovation in Regional Health. • Facilitate and promote the translation of evidence derived from health and medical research into practices, policies and systems designed to prevent illness and improve public health. <p>C. Integrity</p> <ul style="list-style-type: none"> • In partnership with the Australian Research Council and Universities Australia, finalise and release the <i>Australian Code for the Responsible Conduct of Research</i>, to ensure it reflects best practice in ethics and integrity, and develop other supporting guides. • Administer the <i>Research Involving Human Embryos Act 2002</i> and the <i>Prohibition of Human Cloning for Reproduction Act 2002</i>, which prohibits certain practices, including human cloning for reproduction and restrict other practices relating to reproductive technology and research.

Performance criteria				
A. Investment				
Increase research on dementia and its translation into policy and practice.				
2017-18 Estimated result		2018-19 Target		2019-20 (& beyond) Target
Two additional grant rounds were opened between July 2017 and February 2018 to support priority research projects. In addition, outcomes for three grant rounds were announced.		Synthesise outcomes from dementia research to inform improved treatments and care for people with dementia.		As per 2018-19.
Citation rate of journal articles resulting from NHMRC funded research.^{2,3}				
2017-18 Estimated result		2019-20 Target		2022-23 (& beyond) Target
>160% of the average citation rate of all journal articles published worldwide.		>150% of the average citation rate of all journal articles published worldwide.		As per 2019-20.
Support research that will provide better health outcomes for Aboriginal and Torres Strait Islander peoples, through percentage of annual research budget expenditure on Indigenous health research.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
6%	>5%	>5%	>5%	>5%
C. Integrity				
Release the revised <i>Australian Code for the Responsible Conduct of Research (Code)</i> and monitor implementation.				
2017-18 Estimated result		2018-19 Target		2019-20 (& beyond) Target
Revised Code released.		Support Administering Institutions with implementation of the Code.		At least 80% of Administering Institutions report implementation of the Code.
Material changes to Program 1.1 resulting from the following measures:				
There are no material changes to Program 1.1 resulting from measures.				

² This is a triennial measure.

³ Bibliographic citations are the referencing of a journal article in a subsequent journal article, indicating some scientific impact of the original work. The citation rate of journal articles resulting from NHMRC funded research (above) is shown as a proportion of the world citation average, which is determined by dividing the total number of citations by the total number of journal articles published in the world in the same time period. In this measure, the world average, based on publications and citation data available in the Web of Science database, is set to 100%, which means publications are achieving citations as would be expected for that subject area during the specified time period. Therefore, a value of 150%, for example, indicates a citation impact of 50% higher than the world average for similar research worldwide.

Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2018-19 Budget year, including the impact of Budget measures and resourcing on financial statements.

3.1 BUDGETED FINANCIAL STATEMENTS

3.1.1 Differences Between Entity Resourcing and Financial Statements

This section is not applicable to the NHMRC.

3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

Departmental Resources

Comprehensive Income Statement (showing net cost of services)

Revenue and expenditure for 2018-19 is expected to be in line with Government forecasts, with Employee expenses to be 48 per cent of total expenditure.

Balance Sheet

Assets and Liabilities are expected to remain stable across the Budget and forward years.

Administered Resources

The Administered accounts are used as a mechanism to transfer the majority of funds to NHMRC's Special Account (Medical Research Endowment Account). In 2018-19 the transfer to the Special Account is expected to be \$829 million.

3.2 BUDGETED FINANCIAL STATEMENTS TABLES

Table 3.1: Comprehensive Income Statement (showing net cost of services for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
EXPENSES					
Employee benefits	22,025	22,400	22,523	22,150	22,400
Supplier expenses	23,384	22,145	20,231	19,785	18,900
Depreciation and amortisation	2,400	2,600	2,600	2,600	2,600
Total expenses	47,809	47,145	45,354	44,535	43,900
LESS:					
OWN-SOURCE INCOME					
Revenue					
Sale of goods and rendering of services	5,386	6,846	5,124	5,107	4,356
Total revenue	5,386	6,846	5,124	5,107	4,356
Gains					
Other	1,018	108	108	108	108
Total gains	1,018	108	108	108	108
Total own-source income	6,404	6,954	5,232	5,215	4,464
Net cost of (contribution by) services	41,405	40,191	40,122	39,320	39,436
Revenue from Government	39,005	37,591	37,522	36,720	36,836
Surplus (deficit)	(2,400)	(2,600)	(2,600)	(2,600)	(2,600)
Surplus (deficit) attributable to the Australian Government	(2,400)	(2,600)	(2,600)	(2,600)	(2,600)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income (loss)	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(2,400)	(2,600)	(2,600)	(2,600)	(2,600)
Note: Reconciliation of comprehensive income attributable to the agency					
	2017-18 \$'000	2018-19 \$'000	2019-20 \$'000	2020-21 \$'000	2021-22 \$'000
Total comprehensive income (loss) attributable to the Australian Government	(2,400)	(2,600)	(2,600)	(2,600)	(2,600)
plus non-appropriated expenses depreciation and amortisation expenses	2,400	2,600	2,600	2,600	2,600
Total comprehensive income (loss) attributable to the agency	-	-	-	-	-

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Year 1 \$'000	2020-21 Forward Year 2 \$'000	2021-22 Forward Year 3 \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	524	524	524	524	524
Receivables	8,148	7,089	5,739	5,739	5,739
Total financial assets	8,672	7,613	6,263	6,263	6,263
Non-financial assets					
Property, plant and equipment	4,012	2,783	2,904	1,682	461
Inventories	193	193	193	193	193
Intangibles	9,408	9,388	8,438	7,238	6,038
Other	1,157	1,157	1,157	1,157	1,157
Total non-financial assets	14,770	13,521	12,692	10,270	7,849
Total assets	23,442	21,134	18,955	16,533	14,112
LIABILITIES					
Payables					
Suppliers	1,838	1,828	1,828	1,828	1,828
Other payables	2,296	2,271	2,271	2,271	2,271
Total payables	4,134	4,099	4,099	4,099	4,099
Provisions					
Employees	6,012	5,918	5,918	5,918	5,918
Total provisions	6,012	5,918	5,918	5,918	5,918
Total liabilities	10,146	10,017	10,017	10,017	10,017
Net Assets	13,296	11,117	8,938	6,516	4,095
EQUITY					
Contributed equity	15,825	16,246	16,667	16,845	17,024
Retained surpluses or accumulated deficits	(2,529)	(5,129)	(7,729)	(10,329)	(12,929)
Total equity	13,296	11,117	8,938	6,516	4,095

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2018-19)

	Retained earnings \$'000	Asset revaluation reserve \$'000	Contributed equity/ capital \$'000	Total equity \$'000
Opening balance as at 1 July 2018				
Balance carried forward from previous period	(2,529)	-	15,825	13,296
Surplus (deficit) for the period	(2,600)	-	-	(2,600)
Appropriation (equity injection)	-	-	250	250
Capital budget - Bill 1 (DCB)	-	-	171	171
Other movements	-	-	-	-
Estimated closing balance as at 30 June 2019	(5,129)	-	16,246	11,117

DCB = Departmental Capital Budget.

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Goods and services	5,386	6,846	5,124	5,107	4,356
Appropriations	43,164	38,650	38,872	36,720	36,836
Net GST received	1,500	1,500	1,500	1,500	1,500
Total cash received	50,050	46,996	45,496	43,327	42,692
Cash used					
Employees	21,801	22,519	22,523	22,150	22,400
Suppliers	23,917	23,547	22,973	21,177	20,292
Total cash used	45,718	46,066	45,496	43,327	42,692
Net cash from (or used by) operating activities	4,332	930	-	-	-
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	8,382	1,351	421	178	179
Total cash used	8,382	1,351	421	178	179
Net cash from (or used by) investing activities	(8,382)	(1,351)	(421)	(178)	(179)
FINANCING ACTIVITIES					
Cash received					
Equity injections - Bill 2	3,879	250	250	-	-
Capital budget - Bill 1 (DCB)	171	171	171	178	179
Total cash received	4,050	421	421	178	179
Net cash from (or used by) financing activities	4,050	421	421	178	179
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	524	524	524	524	524
Cash and cash equivalents at the end of the reporting period	524	524	524	524	524

DCB = Departmental Capital Budget.

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
CAPITAL APPROPRIATIONS					
Equity injections - Bill 2	3,879	250	250	-	-
Capital budget - Bill 1 (DCB)	171	171	171	178	179
Total capital appropriations	4,050	421	421	178	179
Total new capital appropriations represented by:					
Purchase of non-financial assets	4,050	421	421	178	179
Total items	4,050	421	421	178	179
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriations - equity injection ^(a)	3,879	250	250	-	-
Funded by capital appropriation - DCB ^(b)	171	171	171	178	179
Funded internally from departmental resources	4,332	930	-	-	--
Total acquisitions of non-financial assets	8,382	1,351	421	178	179
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	8,382	1,351	421	178	179
Total cash used to acquire assets	8,382	1,351	421	178	179

^(a) Includes both current Bill 2, prior Act 2/4/6 appropriations and special capital appropriations.

^(b) Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budgets (DCB).

Table 3.6: Statement of Asset Movements (Budget year 2018-19)

	Buildings	Other property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2018				
Gross book value	-	7,613	17,546	25,159
Accumulated depreciation/ amortisation and impairment	-	(3,601)	(8,138)	(11,739)
Opening net book balance	-	4,012	9,408	13,420
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation ordinary annual services	-	171	250	421
By purchase - internal resources	-	-	930	930
Total additions	-	171	1,180	1,351
Other movements				
Depreciation/amortisation expense	-	(1,400)	(1,200)	(2,600)
Total other movements	-	(1,400)	(1,200)	(2,600)
As at 30 June 2019				
Gross book value	-	7,784	18,726	26,510
Accumulated depreciation/ amortisation and impairment	-	(5,001)	(9,338)	(14,339)
Closing net book balance	-	2,783	9,388	12,171

Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants - MREA	853,091	844,199	844,732	863,136	878,490
Grants - dementia	40,000	40,000	-	-	-
Suppliers	25,642	13,429	11,946	12,125	12,307
Total expenses administered on behalf of Government	918,733	897,628	856,678	875,261	890,797
REVENUES ADMINISTERED ON BEHALF OF GOVERNMENT					
Sales of Good and Services	3,000	3,000	3,000	3,000	3,000
Recoveries	5,000	5,000	5,000	5,000	5,000
Other non-tax revenue	3,000	3,000	3,000	3,000	3,000
Total income administered on behalf of Government	11,000	11,000	11,000	11,000	11,000

MREA = Medical Research Endowment Account.

Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	185,777	181,617	190,348	193,324	193,324
Receivables	1,883	1,883	1,883	1,883	1,883
Total financial assets	187,660	183,500	192,231	195,207	195,207
Total assets administered on behalf of Government	187,660	183,500	192,231	195,207	195,207
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Grants	2,949	2,949	2,949	2,949	2,949
Other	238	238	238	238	238
Total payables	3,187	3,187	3,187	3,187	3,187
Total liabilities administered on behalf of Government	3,187	3,187	3,187	3,187	3,187

Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Estimate \$'000	2020-21 Forward Estimate \$'000	2021-22 Forward Estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Sales of Goods and Services	3,000	3,000	3,000	3,000	3,000
Cash received - other	8,000	8,000	8,000	8,000	8,000
Net GST received	26,000	26,000	26,000	26,000	26,000
Total cash received	37,000	37,000	37,000	37,000	37,000
Cash used					
Grant payments - MREA	841,673	844,484	845,035	863,431	879,238
Grant payments – Boosting Dementia Research Initiative	40,000	40,000	-	-	-
Suppliers	25,642	13,429	11,946	12,125	12,307
Net GST paid	26,000	26,000	26,000	26,000	26,000
Total cash used	933,315	923,913	882,981	901,556	917,545
Net cash from (or used by) operating activities	(896,315)	(886,913)	(845,981)	(864,556)	(880,545)
Net increase (or decrease) in cash held	(896,315)	(886,913)	(845,981)	(864,556)	(880,545)
Cash at beginning of reporting period	198,460	185,777	181,617	190,348	193,324
Cash from Official Public Account for: - appropriations	883,632	882,753	854,712	867,532	880,545
Cash at end of reporting period	185,777	181,617	190,348	193,324	193,324

MREA = Medical Research Endowment Account.